Table 2.
Outputs N = 620 | Phase 1 N = 273 | Phase 2 N = 347 | Pearson χ2 (P value) | Policy reference N = 1746 | Phase 1 N = 1099 | Phase 2 N = 647 | Pearson χ2 (P value) | |
---|---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||
Severity/HC demand and capacity | 123 (19.8) | 54 (19.8) | 69 (19.9) | 0.001 (0.974) | 269 (15.4) | 218 (19.8) | 51 (7.9) | 44.650 (< 0.001)* |
Non-pharmaceutical interventions (NPIs) | 96 (15.5) | 42 (15.4) | 54 (15.6) | 0.004 (0.952) | 453 (25.9) | 342 (31.1) | 111 (17.2) | 41.325 (< 0.001)* |
Surveillance/testing | 90 (14.5) | 38 (13.9) | 52 (15.0) | 0.140 (0.708) | 147 (8.4) | 84 (7.6) | 63 (9.7) | 2.316 (0.128) |
Variants/genomics | 82 (13.2) | 21 (7.7) | 61 (17.6) | 13.014 (< 0.001)* | 264 (15.1) | 63 (5.7) | 201 (31.1) | 203.658 (< 0.001)* |
Transmission | 48 (7.7) | 27 (9.9) | 21 (6.1) | 3.151 (0.076) | 102 (5.8) | 52 (4.7) | 50 (7.7) | 6.647 (0.010)* |
Secondary impact | 44 (7.1) | 24 (8.8) | 20 (5.8) | 2.124 (0.145) | 187 (10.7) | 99 (9.0) | 88 (13.6) | 8.984 (0.003)* |
Vaccines | 32 (5.2) | 5 (1.8) | 27 (7.8) | 11.049 (< 0.001)* | 66 (3.8) | 28 (2.5) | 38 (5.9) | 12.382 (< 0.001)* |
Outbreak scale/under-ascertainment | 28 (4.5) | 24 (8.8) | 4 (1.2) | 20.674 (< 0.001)* | 134 (7.7) | 118 (10.7) | 16 (2.5) | 39.252 (< 0.001)* |
Health systems/policy | 19 (3.1) | 6 (2.2) | 13 (3.7) | 1.233 (0.267) | 14 (0.8) | 5 (0.5) | 9 (1.4) | 4.486 (0.034)* |
Other | 18 (2.9) | 11 (4.0) | 7 (2.0) | 2.194 (0.139) | 7 (0.4) | 5 (0.5) | 2 (0.3) | 0.217 (1.000)^ |
Behaviour/mobility | 16 (2.6) | 11 (4.0) | 5 (1.4) | 4.072 (0.044)* | 80 (4.6) | 71 (6.5) | 9 (1.4) | 23.938 (< 0.001)* |
Clinical/treatment | 13 (2.1) | 6 (2.2) | 7 (2.0) | 0.024 (0.876) | 12 (0.7) | 11 (1.0) | 1 (0.2) | 4.274 (0.039)* |
Economics | 11 (1.8) | 4 (1.5) | 7 (2.0) | 0.267 (0.605) | 11 (0.6) | 3 (0.3) | 8 (1.2) | 6.039 (0.014)* |
* Significant (P < 0.05), ^Fisher’s exact test considering outputs published in one theme compared to all other outputs and the difference between the two phases